Platelet aggregation inhibitor
BILINTA is indicated to reduce the rate of
cardiovascular death, myocardial infarction (MI), and stroke
in patients with acute coronary syndrome (ACS) or a history
of myocardial infarction. For at least the first 12 months
following ACS, it is superior to clopidogrel.
BILINTA also reduces the rate of stent thrombosis in patients
who have been stented for treatment of ACS.
Ticagrelor is a platelet aggregation inhibitor works by blocking platelets from sticking together and prevents them from forming harmful clots. It is an antiplatelet drug. It keeps blood flowing smoothly in your body.
Ticagrelor is used along with low-dose aspirin to help prevent heart attack and stroke in people with heart problems (such as unstable angina, previous heart attack). It may also be used to prevent heart attack or stroke after certain heart surgeries (such as stent placement, coronary artery bypass graft-CABG, or angioplasty).